By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Amoy Diagnostics this week received marketing approval from China's State Food and Drug Administration for its EGFR and BRAF tests for clinical use.

The AmoyDx EGFR assay tests for mutations in the tyrosine kinase domain associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). According to the Ziamen, China-based firm, the test also detects the T790M mutation that is associated with resistance to treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.